e-ISSN: 2394-2967
logo

British Journal of Medical and Health Research

LoginTrack

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

Volume 7, Issue 11 - 2020 (November 2020 Issue 11)

Volume 7 Issue 11 Cover

Issue Details:

Volume 7 Issue 11
Published:Invalid Date

Editorial: November 2020 Issue 11

Welcome to the 2020 issue of British Journal of Medical and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr Hemangi J Patel
Editor-in-Chief
British Journal of Medical and Health Research

Articles in This Issue

Showing 4 of 4 articles
Research PaperID: BJMHR0711001

ISOLATION AND CHARACTERIZATION OF SECONDARY METABOLITES AND EVALUATION OF BIOLOGICAL ACTIVITY OF Hygrophila erecta (Burm.f.) Hochr.

Faria Mannan Mithi, Monira Ahsan, Choudhury Mahmood Hasan, A. T. M. Zafrul Azam

Hygrophila erecta (Burm.f.) Hochr. belonging to the Acanthaceae family, is a moisture loving genera and a perennial herb whose seeds are used as a skin-regenerating product. The concentrated ethyl acetate soluble fraction of methanolic extract of this whole plant resulted in a mixture of a mixture of 4-methoxybenzoic acid and 4-methoxycinnamic acid, another mixture of two ester derivatives: methyl linoleate and methyl stearate, lupeol, β-Sitosterol and Stigmasterol. The crude methanolic extract of the whole plant was partitioned to petroleum ether soluble fraction, chloroform soluble fraction, ethyl acetate soluble fraction and aqueous soluble fraction for the purpose of investigations of different biological activities. The ethyl acetate soluble fraction expressed the highest antioxidant property in DPPH free radical scavanging method, whilst the different extractives exhibited moderate to strong cytotoxicity in brine shrimp lethality test and the highest activity was shown by pet ether soluble fraction. Furthermore, the pet ether soluble fraction also demonstrated highest thrombolytic activity compared to the standard streptokinase, while the other fractions showed moderate to lower activity. However, no antimicrobial activity was observed for any of the fractions investigated using standard tetracycline and ciprofloxacin. The methanolic extract further produced statistical significant peripheral analgesic and antidiarrheal activity at both 200 mg/kg and 400 mg/kg doses. Although, it expressed blood glucose lowering activity, but it was not statistical significant.

Hygrophila erecta (Burm.f.) Hochr.AcanthaceaeMethyl linoleate and methyl stearate4-methoxybenzoic acid and 4-methoxycinnamic acidAntioxidantCytotoxicity.
45,313 views
13,588 downloads
DOI:
10.46624/bjmhr.2020.v7.i11.001

Contributors:

 Faria Mannan Mithi
,
 Monira Ahsan
,
 Choudhury Mahmood Hasan
,
 A. T. M. Zafrul Azam
Research PaperID: BJMHR0711002

Studies on the Anticancer Activities of Folic Acid in Combination with Multivitamins in Colon Cancer Rats Induced by Azoxymethane

Osama Abdulrahman SHAIKHOMAR, Osama Abdulrahman SHAIKHOMAR

Colorectal cancer one of the mostly found cancer in all over the world. Mortality rate by this cancer is high compared to other types o cancers. Early diagnosis of this cancer is required to treat this cancer. Many drugs are being used to treat this disease but they all have many side effects so in study we tried to overcome this issue by treating this cancer with supplements. We used male albino SD rats to conduct this study. We divided the rats into 7 groups in which 4 of them were given Azoxymethane (AOM) to induce the colo-rectal cancer while remaining 3 were kept control. One group with AOM was not given any treatment while 3 received folic acid dose (20, 40, and 60) respectively along with Vitamin A, C, and E supplementation. Control groups without AMO were also treated with same doses of folic acid in order to compare the results. Results reveal that Folic acid improved GSH, TAC, Lipid peroxidation and superoxide dismutase levels in the AMO treated groups. These tests were also improved in control groups with folic acid and vitamin supplementation. We conclude that Folic acid is found very affective against the colorectal cancer without harming the natural mechanisms in the body. The aim of this study, to evaluate the preventive and protective measure of different doses of folic acid with normal therapeutic doses of vitamin A, C and E against azoxymethane induce colon cancer in rat.

Colon and rectum cancerFolic acidVitaminCAzoxymethaneSuperoxide dismutaseGSH
45,510 views
13,686 downloads
DOI:
10.46624/bjmhr.2020.v7.i11.002

Contributors:

 Osama Abdulrahman SHAIKHOMAR
,
 Osama Abdulrahman SHAIKHOMAR
Research PaperID: BJMHR0711003

COVID-19, an emerging coronavirus infection: Advances and prospects in designing convalescent sera , immunotherapeutics and therapeutics

SUMAN SAURABH GUPTA, Monika Upadhyay, V.D Dafle

As of early 2020, humanity is try an epidemic in severe acute metastasis syndrome coronavirus a combine of (SARS-CoV-2).SARS-CoV-2 causes coronavirus illness, abbreviated as COVID-19. With COVID-19, the degree of unhealthiness varies, starting from well to sharp and fatal. the planet Health Organization estimates that serious unhealthiness may occur in as many as 13.8% of cases and 6.1% unit of measurement essential. This Viewpoint argues that human convalescent humour is Associate in Nursing chance for bar and treatment of COVID-19 illness. convalescent sera could be accustomed treat folks with early symptoms and stop illness in those exposed. Hence, as we have a tendency to tend to unit of measurement within the within of a worldwide pandemic, we have a tendency to tend to advocate that institutions deem the emergency use of convalescent sera and begin preparations as presently as achievable. The novel coronavirus infection (COVID-19 or Coronavirus unwellness 2019) that emerged from Wuhan, Hubei province of China has unfold to several countries worldwide. Efforts are created to develop vaccines against human coronavirus (CoV) infections like MERS and SARS within the past decades. However, to date, no authorised antiviral treatment or immunizing agent exists for MERS and SARS. Most of the efforts for developing CoV vaccines and medicines target the spike supermolecule|compound protein} or S protein, the most important inducer of neutralizing antibodies. though a couple of candidates have shown effectualness in in vitro studies, not several have progressed to randomised animal or human trials, thence might have restricted use to counter COVID-19 infection. this text highlights in progress advances in coming up with vaccines and medical specialty to counter COVID-19 whereas additionally that specialize in such experiences and advances as created with earlier SARS- and MERS-CoVs, that along may modify efforts to halt this rising viral infection

PLASMAPHERESISMORBILLIGRIPPECORONAVIRUSMONOCLONAL ANTIBODY
46,018 views
13,660 downloads
DOI:
10.46624/bjmhr.2020.v7.i11.003

Contributors:

 SUMAN SAURABH GUPTA
,
 Monika Upadhyay
,
 V.D Dafle
Research PaperID: BJMHR0711004

Validation Of Uterine Artery Doppler In Predicting Intra-Uterine Growth Restriction Among Pregnant Women With Pre-Existing Hypertension

Misbah Hanif, Syeda Batool Mazhar

ABSTRACT Hypertensive disorders complicate 12% to 22% of all pregnancies. Intrauterine growth restriction is one of the fetal outcomes in mothers with hypertension. Doppler studies are done to predict pregnancy outcome in patients with hypertension. We planned this study to determine the role of uterine artery Doppler at 22 to 26 weeks of gestation for predicting IUGR in women with pre-existing hypertension. A cross sectional validation study was undertaken in the Department of Obstetrics & Gynaecology, MCH Center, Unit I, PIMS, Islamabad from June 2014 to June 2015. Both primigravida and multigravida women with pre-existing hypertension were enrolled. Pregnancies with congenital abnormalities, complications like diabetes, cardiac disease and autoimmune disease were excluded. Women without satisfactory attainment of sonography due to technical reasons, lost to follow-up and cases who were not delivered in MCH Center, PIMS, were also excluded. There were 15 (26.7%) cases of IUGR in normal RI Doppler group and 20 (35.7%) abnormal RI Doppler group. The average birth weight was slightly higher in normal RI group 2.9 + 1.1 kg compared to 2.3 + 0.7 kg in abnormal RI group. RI on Doppler ultrasound had sensitivity and specificity of 57.1% and 53.2% in predicting IUGR whereas the PPV and NPV were found to be 35.7% and 73.2% respectively. RI on Doppler ultrasound is a reasonably good predictor of IUGR. Though it was reasonably sensitive the value of PPV was not that high (35.7%). Keywords; Pregnancy, pre-existing hypertension, uterine artery Doppler, IUGR

Pregnancypre-existing hypertensionuterine artery DopplerIUGR
45,815 views
13,829 downloads
DOI:
10.46624/bjmhr.2020.v7.i11.004

Contributors:

 Misbah Hanif
,
 Syeda Batool Mazhar

Related Issues

Volume 13, Issue 1

2026 • 2 articles

Volume 12, Issue 12

2025 • 2 articles

Volume 12, Issue 11

2025 • 2 articles

Volume 12, Issue 10

2025 • 2 articles